Intranasally administered corticosteroids and neuropsychiatrie disturbances: A review of the International Pharmacovigilance Programme of the World Health Organization

Annals of Allergy, Asthma and Immunology

Volumn 101, Issue 1, 2008, Pages 67-73

  Pokladnikova, Jitka ^a   Meyboom, Ronald H B ^b,c   Vlcek, Jiri ^a   Edwards, Ralph I ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UPPSALA MONITORING CENTRE   (Sweden)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; APREPITANT; BECLOMETASONE DIPROPIONATE; BETAMETHASONE SODIUM PHOSPHATE; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; DILTIAZEM; FLUNISOLIDE; FLUTICASONE PROPIONATE; MACROLIDE; MOMETASONE FUROATE; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEX HORMONE; TIXOCORTOL PIVALATE; TRIAMCINOLONE ACETONIDE;

ABNORMAL THINKING; AGGRESSION; AGITATION; ALLERGY; AMNESIA; ANOREXIA; ANXIETY; APATHY; APPETITE DISORDER; ARTICLE; COMA; CONCENTRATION LOSS; CONFUSION; CONVULSION; DATA BASE; DELUSION; DEPERSONALIZATION; DEPRESSION; DISEASE ASSOCIATION; DREAM; DREAMING; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; EUPHORIA; GRAND MAL SEIZURE; HALLUCINATION; HUMAN; HYSTERIA; INCREASED APPETITE; INFORMATION PROCESSING; INSOMNIA; INTRACRANIAL HYPERTENSION; MANIA; MENTAL DISEASE; MENTAL INSTABILITY; MIGRAINE; NERVOUSNESS; NEUROLOGIC DISEASE; NEUROSIS; NOSE POLYP; PARANOIA; PERSONALITY DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SLEEP WALKING; SOMNOLENCE; STUPOR; SUICIDE ATTEMPT; WORLD HEALTH ORGANIZATION;

EID: 47349101628     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60837-X     Document Type: Article

References (32)

1. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(suppl):S147-S334.
2. Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy. 2000;55:16-33.
3. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf. 2003;26:863-893.
4. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther. 1999;83:153-179.
5. US Food and Drug Administration [homepage on the Web]. Rhinocort Aqua (budesonide) nasal spray, 32 mcg. Available at: http://www.fda.gov/medwatch/ SAFETY/2003/03SEP_PI/Rhinocort_PI.pdf. Accessed December 1, 2006.
6. US Food and Drug Administration [homepage on the Web]. Beconase AQ (beclomethasone dipropionate, monohydrate) nasal spray, 42 mcg. Available at: http://www.fda.gov/medwatch/SAFETY/2005/Oct_PI/ BeconaseAQ_PI.pdf. Accessed December 1, 2006.
7. US Food and Drug Administration [homepage on the Web]. Nasonex (mometasone furoate monohydrate) nasal spray, 50 mcg. Available at: http://www.fda.gov/cder/foi/label/2000/20762S91bl.pdf. Accessed December 1, 2006.
8. WHO Collaborating Centre for International Drug Monitoring. Uppsala Monitoring Centre [homepage on the Web]. Available at: http://www.who-umc.org. Accessed December 1, 2006.
9. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 2000;23:11-33.
10. Gawchik SM, Saccar CL. A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. Drug Saf. 2000;23:309-322.
11. Daley-Yates P, Price AC, Pereira A, Richards DH. Absolute bioavailability of beclomethasone dipropionate administered via the inhaled, intra-nasal and oral routes in man. Allergy. 2000;55:952.
12. Thorsson L, Borga O, Edsbacker S. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous spray pump and powder. Br J Clin Pharmacol. 1999;47:619-624.
13. Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Br J Clin Pharmacol. 2001;51:103-105.
14. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11:1-18.
15. Talegaonkar S, Mishra PR. Intranasal delivery: an approach to bypass the blood brain barrier. Indian J Pharmacol. 2004;36:140-147.
16. Martindale, the Extra Pharmacopoeia. London, England: London Pharmaceutical Press; 2004.
17. Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003;25:27-33.
18. Vincent FM. The neuropsychiatric complications of corticosteroid therapy. Compr Ther. 1995;21:524-528.
19. Meyboom RHB. Adverse reaction to drugs in children, experiences with "spontaneous monitoring" in the Netherlands. Bratisl Lek Listy. 1991;92:554-559.
20. Goldstein ET, Preskorn SH. Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. Am J Psychiatry. 1989;146:1076-1077.
21. Phelan MC. Beclomethasone mania. Br J Psychiatry. 1989;155:871-872.
22. Lewis LD, Cochrane GM. Psychosis in a child inhaling budesonid. Lancet. 1983;2:634.
23. Meyboom RHB, De Graaf-Breederveld N. Budesonide and psychic side effects. Ann Intern Med. 1988;109:683.
24. Hederos CA. Neuropsychiatric changes and inhaled corticosteroids. J Allergy Clin Immunol. 2004;114:451-452.
25. de Vries TW, de Langen-Wouterse JJ, van Puijenbroek E, Duiverman EJ, de Jong-Van den Berg LT. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol. 2006;62:343-346.
26. Sheffer AL, Silverman M, Woolcock AJ, Diaz PV, Lindberg B, Lindmark B. Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy-Asthma Immunol. 2005;94:48-54.
27. Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2006;96:514-525.
28. Korte SM. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev. 2001;25:117-142.
29. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19:269-301.
30. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr. 2004;26:189-201.
31. Van Grootheest K, De Jong-van den Berg L. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf. 2004;3:363-368.
32. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385-396.